acut
lung
injuri
acut
respiratori
distress
syndrom
ard
repres
heterogen
group
lung
diseas
critic
ill
patient
continu
high
mortal
despit
increas
understand
molecular
pathogenesi
ard
specif
target
treatment
ard
yet
develop
ard
repres
unmet
medic
need
urgenc
develop
effect
pharmacotherapi
multipl
promis
target
identifi
could
lead
develop
potenti
therapi
ard
howev
limit
difficulti
mode
deliveri
especi
critic
ill
patient
nanobiotechnolog
basi
innov
techniqu
deliv
drug
target
site
inflam
organ
lung
nanoscal
drug
deliveri
system
abil
despit
recent
advanc
diagnost
therapeut
modal
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
still
repres
unmet
medic
need
high
morbid
mortal
substanti
medic
expenditur
henc
urgent
need
develop
novel
approach
treat
ard
unfortun
contemporari
drug
develop
approach
address
challeng
reward
particular
blockad
singl
cytokin
chemokin
fail
show
improv
outcom
complex
pathogenesi
natur
diseas
therefor
defin
contribut
proxim
signal
pathway
amplifi
inflammatori
respons
develop
target
therapi
specif
block
attract
approach
limit
injuri
inflamm
devast
diseas
end
identifi
sever
target
modul
signal
pathway
amplifi
inflamm
henc
attract
test
potenti
therapi
ali
ard
howev
deliveri
peptid
protein
silenc
rna
lung
ongo
challeng
nanosci
studi
nanoscal
materi
process
devic
recent
year
nanomedicin
becom
attract
concept
target
deliveri
therapeut
diagnost
compound
lung
nanoparticl
drug
deliveri
system
use
provid
deliveri
drug
improv
bioavail
sustain
releas
drug
system
deliveri
system
abil
improv
pharmacokinet
pharmacodynam
agent
allow
increas
biodistribut
therapeut
agent
target
organ
result
improv
efficaci
minim
drug
toxic
nanocarri
special
design
target
inflamm
cancer
permeabl
vasculatur
among
variou
drug
deliveri
system
consid
pulmonari
applic
use
biodegrad
polymer
nanoparticl
repres
sever
advantag
treatment
respiratori
diseas
method
particularli
attract
deliveri
molecular
target
set
critic
ill
adult
respiratori
distress
syndrom
sepsi
number
differ
strategi
propos
modif
nanoparticl
characterist
control
behavior
within
biolog
environ
cellspecif
target
drug
deliveri
modifi
biolog
distribut
drug
cellular
organ
level
method
deliveri
particularli
attract
inflammatori
condit
ali
ard
accordingli
har
uniqu
attribut
novel
longact
biocompat
biodegrad
antiinflammatori
nanomedicin
test
cell
murin
model
inflamm
consist
amphipath
peptid
drug
human
glucagonlik
amid
trigger
receptor
express
myeloid
cell
block
peptid
waterinsolubl
cytotox
drug
innov
approach
consist
selfassembl
drug
us
fdagener
regardedassaf
distearoylphosphatidylethanolamin
coval
link
polyethylen
glycol
molecular
weight
dspepeg
compon
us
fdaapprov
doxil
form
longact
biocompat
biodegrad
steric
stabil
phospholipid
micel
aqueou
milieu
ssm
size
nm
ali
ard
aris
direct
indirect
injuri
lung
result
lifethreaten
form
respiratori
failur
diffus
bilater
lung
injuri
sever
hypoxemia
caus
noncardiogen
pulmonari
edema
affect
approxim
million
peopl
worldwid
annual
import
lung
injuri
highlight
emerg
sar
sever
acut
respiratori
syndrom
mer
middl
eastern
respiratori
syndrom
major
reason
underli
lag
improv
outcom
lack
novel
specif
therapi
ali
ard
inflammatori
process
lung
inflamm
accompani
mani
cellular
biochem
process
injuri
pulmonari
capillari
endothelium
alveolar
epithelium
despit
improv
molecular
understand
develop
specif
treatment
ard
yet
develop
molecular
pathobiolog
ard
extens
defin
role
sever
molecul
includ
pattern
recognit
receptor
present
immun
cell
eg
tolllik
receptor
nodlik
receptor
inflammasom
downstream
signal
molecul
effector
molecul
eg
investig
pathogenesi
ali
ard
target
central
molecul
attenu
lung
inflamm
major
limit
inhibit
immunosuppress
compromis
host
defens
howev
due
complex
natur
diseas
target
singl
cytokin
chemokin
also
fail
attenu
lung
inflamm
suffici
singli
attenu
lung
inflamm
ard
thu
propos
innov
approach
involv
use
peptid
antiinflammatori
target
target
upstream
molecul
reactiv
oxygen
speci
lead
activ
ultim
lead
ali
ard
poor
outcom
mani
case
fig
develop
novel
approach
deliv
inhibitor
molecul
vivo
shown
individu
nanoformul
effect
attenu
lung
inflamm
murin
model
steric
stabil
phospholipid
nanomicel
ssm
novel
longact
biocompat
biodegrad
phospholipidbas
drug
deliveri
vehicl
act
versatil
carrier
platform
peptid
waterinsolubl
drug
approach
entail
selfassembl
distearoylphosphatidylethanolamin
coval
link
polyethylen
glycol
molecular
weight
dspepeg
drug
form
steric
stabil
phospholipid
nanomicel
aqueou
milieu
ssm
size
nm
diamet
nanomicel
compos
hydrophil
corona
hous
amphipath
peptid
drug
peptid
fig
anim
hydrophob
core
accommod
waterinsolubl
drug
simpl
prepar
unlik
liposom
store
lyophil
form
without
lyoor
cryoprotect
extend
period
time
nanoparticl
construct
variou
methodolog
effect
target
desir
site
nanomicel
stabil
peptid
activ
biolog
form
prefer
ligandreceptor
interact
prevent
rapid
peptid
degrad
vivo
therebi
prolong
bioactiv
unlik
surfact
micel
low
critic
micellar
concentr
nanoparticl
prevent
disintegr
upon
dilut
biolog
fluid
importantli
peg
moieti
ssm
confer
steric
hindranc
circul
nanos
mitig
renal
clearanc
extravas
intact
microvessel
turn
prolong
circul
time
drugload
nanomicel
promot
preferenti
extravas
hyperperm
lung
microcircul
hallmark
ali
injur
lung
particular
deliveri
system
shown
increas
stabil
wide
varieti
therapeut
agent
hydrophob
molecul
peptid
oliginucleotid
system
exploit
diagnost
therapeut
purpos
carri
drug
bodi
control
manner
site
administr
therapeut
target
impli
passag
drug
molecul
drug
deliveri
system
across
numer
physiolog
barrier
repres
challeng
goal
drug
target
innov
passiv
target
therapeut
strategi
amplifi
drug
deliveri
lung
therebi
maxim
efficaci
enhanc
resolut
inflamm
reduc
collater
damag
innoc
bystand
organ
nanomicel
approv
fda
human
studi
begin
address
potenti
nanotechnolog
treatment
ard
develop
novel
longact
biocompat
biodegrad
phospholipid
micel
size
nm
modul
key
signal
molecul
critic
inflammatori
respons
ali
ard
select
molecul
initi
propag
inflammatori
respons
distinct
mechan
multipl
pathway
target
either
singli
combinatori
approach
diseas
like
hiv
amongst
reactiv
oxygen
speci
pleiotrop
potent
antiinflammatori
peptid
initi
select
modul
inflammatori
respons
lung
realiz
short
halflif
peptid
drug
minut
hamper
clinic
use
invent
micellar
peptid
peptid
drug
stabil
activ
form
bioactiv
prolong
hour
vivo
likewis
water
insolubl
select
inhibitor
constrain
use
human
accordingli
selfassoci
micel
overcom
limit
time
increas
stabil
bioavail
longact
micellar
drug
provid
signific
advanc
treatment
experiment
ali
could
extend
critic
ill
patient
nanoparticl
introduc
system
administr
oral
dermal
intraven
etc
directli
lung
inhal
intranas
oropharyng
aspir
system
deliveri
nanoparticl
base
principl
passiv
target
passiv
target
occur
result
extravas
nanoparticl
diseas
site
microvasculatur
leaki
ard
recent
test
efficaci
nanomicel
mous
model
lipopolysaccharid
lp
induc
lung
injuri
mice
week
old
treat
lp
nebul
concentr
mgml
administ
via
devilbiss
dispos
nebul
continu
air
flow
rate
ft
h
h
induc
ali
ssm
treatment
administ
via
subcutan
rout
dose
nmol
control
mice
treat
ssm
scrambl
peptid
empti
ssm
mice
receiv
lp
nebul
mgml
previous
shown
model
induc
neutrophil
influx
lung
assess
magnitud
lung
inflamm
total
neutrophil
cell
count
proinflammatori
cytokin
level
total
neutrophil
count
bronchoalveolar
lavag
fluid
myeloperoxidas
activ
lung
tissu
measur
vivo
administr
lpsinduc
ali
mice
result
signific
downregul
lung
inflamm
dosedepend
antiinflammatori
activ
observ
similar
therapeut
activ
detect
salin
indic
ssm
nanocarri
play
critic
role
protect
enzymelabil
deliv
inflam
tissu
vivo
studi
demonstr
first
time
lipidbas
nanoformul
effect
attenu
inflamm
aliard
also
test
efficaci
nanomicellar
peptid
model
lpsinduc
sepsi
lung
injuri
trem
protein
famili
immunoglobulin
cell
surfac
receptor
express
myeloid
cell
first
trem
identifi
blockad
shown
improv
surviv
anim
model
sepsi
extens
studi
mechan
amplifi
inflamm
previou
studi
blockad
use
therapeut
model
sepsi
infect
employ
fusion
protein
solubl
extracellular
compon
peptid
limit
short
halflif
therefor
may
practic
therapeut
purpos
effect
block
express
develop
peptid
nanomedicin
solubl
extracellular
compon
bind
inhibit
signal
control
ssm
prepar
use
scrambl
peptid
block
peptid
circular
dichroism
confirm
signific
increas
presenc
ssm
compar
free
peptid
normal
salin
indic
presenc
peptidemicel
interact
peptid
chang
random
conform
salin
order
helic
structur
associ
ssm
determin
vivo
antiinflammatori
efficaci
doserespons
effect
establish
dose
timedepend
effect
mice
given
one
dose
nanomedicin
nanoscrambl
peptid
pb
subcutan
singl
dose
prior
lp
challeng
ali
anim
model
use
base
previou
public
mice
challeng
aerosol
lp
nebul
mg
lp
dissolv
phosphatebuff
salin
concentr
mgml
administ
via
devilbiss
dispos
nebul
continu
air
flow
rate
ft
h
h
induc
ali
anim
sacrif
h
lp
nebul
firstli
detect
fold
chang
gene
induc
nanomedicin
lung
mice
inhibit
express
howev
significantli
lower
express
gene
respons
nanomedicin
furthermor
inflammatori
paramet
includ
total
neutrophil
cell
count
cytokin
chemokin
lung
myeloperoxidas
significantli
lower
mice
receiv
nanomedicin
compar
control
group
data
suggest
nanomicellar
prepar
inhibitori
peptid
efficaci
nake
peptid
effect
mitig
lung
inflamm
lpsinduc
lung
injuri
studi
nanomicellar
prepar
curcumin
agonist
treatment
aliard
current
ongo
laboratori
togeth
studi
demonstr
feasibl
translat
use
nanomicellar
prepar
translat
human
studi
clinic
treat
devast
diseas
hypothes
combinatori
administr
nanomicel
use
pleiotrop
agent
modul
multipl
signal
pathway
prove
potent
howev
studi
need
optim
administr
nanoprepar
work
focus
target
macrophag
immun
cell
lung
injuri
howev
vascular
endothelium
repres
import
therapeut
target
lung
injuri
especi
system
condit
sepsi
sever
studi
focus
target
vascular
endothelium
especi
molecul
defici
overexpress
lung
injuri
studi
anim
model
investig
nanocarri
target
endotheli
cell
shuvaev
muzykantov
use
vascular
immun
target
modul
reactiv
oxygen
speci
produc
enzym
encapsul
proteaseresist
carrier
mous
model
lpsinduc
lung
injuri
antipecam
liposom
load
potent
superoxid
dismutasecatalas
mimet
enhanc
target
endothelium
compar
control
iggcoat
liposom
liposom
allevi
lpsinduc
lung
injuri
suggest
antipecameukliposom
may
use
allevi
acut
pulmonari
inflamm
ferrer
et
al
use
dexamethason
encapsul
nanogel
model
pulmonari
inflamm
nanogel
nanos
network
absorb
larg
amount
water
preserv
structur
via
physic
chemic
crosslink
contrast
tradit
nanoparticl
nanogel
deform
pass
physiolog
filter
result
greater
deliveri
effici
reach
use
stiffer
nanoparticl
use
nanogel
show
enhanc
deliveri
dex
lung
reduc
toxic
free
dex
nontarget
organ
show
nanogel
allevi
pulmonari
inflamm
scant
data
target
lung
epithelium
use
system
approach
mous
model
lpsinduc
lung
injuri
lin
et
al
test
polyethylenimin
dna
nanoparticl
target
adrenerg
receptor
studi
show
treatment
polyethylenimin
adrenerg
receptor
improv
surviv
mice
lethal
lpsinduc
lung
injuri
togeth
studi
show
potenti
target
specif
molecul
cell
type
use
nanomedicin
approach
mitig
lung
injuri
inflamm
sepsi
common
caus
ali
continu
major
caus
morbid
mortal
despit
time
appropri
administr
antibiot
host
inflammatori
respons
overwhelm
lead
multiorgan
failur
death
addit
emerg
multidrugresist
bacteria
continu
press
threat
besid
antibiot
altern
approach
enhanc
bacteri
clearanc
physic
destruct
bacteria
separ
bacteria
blood
develop
microfluidicmicromagnet
separ
bacteria
studi
vitro
order
develop
novel
method
remov
bacteria
bloodstream
also
propos
bacteria
clear
physic
destruct
experiment
model
approach
use
photodynam
therapi
shown
destroy
bacteria
lee
et
al
develop
approach
clear
bacteria
bloodstream
use
magnet
nanoparticl
modifi
synthet
ligand
zinccoordin
bi
dipicolylamin
methodolog
util
highli
select
rapid
separ
bacteria
toxin
whole
blood
use
magnet
microfluid
devic
microvascular
leaki
ali
ard
result
increas
permeabl
presenc
inflammatori
vasoact
factor
enhanc
permeabl
thu
drug
use
treatment
ali
ard
administ
system
local
lung
passiv
target
innov
passiv
target
therapeut
strategi
amplifi
drug
deliveri
lung
therebi
maxim
efficaci
enhanc
resolut
inflamm
reduc
collater
damag
innoc
bystand
organ
occur
patient
ali
ard
among
variou
drug
deliveri
system
consid
pulmonari
applic
nanoparticl
compos
biodegrad
lipidbas
nanomicel
polym
fulfil
mani
requir
place
deliveri
system
abil
transfer
aerosol
stabil
forc
gener
aerosol
biocompat
target
specif
site
cell
popul
lung
releas
drug
predetermin
manner
degrad
within
accept
period
time
clearli
studi
warrant
establish
role
aerosol
nanoprepar
inhal
therapi
current
use
deliveri
system
low
predetermin
lungsit
deposit
effici
drug
deposit
devicespac
much
higher
amount
oral
caviti
henc
direct
drug
deliveri
requir
lung
site
becom
activ
research
area
target
drug
deliveri
respiratori
drug
effici
administ
deeper
lung
region
interest
without
signific
loss
oralupp
airway
specif
target
deliveri
respiratori
drug
use
modifi
inhal
devic
achiev
control
releas
drug
aerosol
devic
henc
urgent
need
develop
aerosol
prepar
target
lung
far
use
nanomicellar
prepar
deliveri
target
drug
lung
use
system
approach
control
drug
deliveri
system
also
becom
increasingli
attract
option
inhal
therapi
larg
surfac
area
lung
minim
barrier
imped
access
lung
peripheri
make
organ
suitabl
portal
varieti
therapeut
intervent
blood
barrier
alveolar
space
pulmonari
capillari
thin
allow
rapid
ga
exchang
alveoli
small
approxim
million
lung
although
alveoli
tini
structur
larg
surfac
area
total
perform
effici
ga
exchang
make
attract
organ
direct
drug
deliveri
among
variou
drug
deliveri
system
consid
pulmonari
applic
nanoparticl
demonstr
sever
advantag
treatment
respiratori
diseas
prolong
drug
releas
cellspecif
target
drug
deliveri
modifi
biolog
distribut
drug
cellular
organ
level
nanoparticl
compos
biodegrad
polym
fulfil
mani
requir
place
deliveri
system
abil
transfer
aerosol
stabil
forc
gener
aerosol
biocompat
target
specif
site
cell
popul
lung
releas
drug
predetermin
manner
degrad
within
accept
period
time
ali
intrins
surfact
inactiv
via
albumin
leakag
potenti
mechan
current
exist
intratrach
surfact
proven
benefici
employ
novel
nanovesicl
aerosol
nonlamellar
lipid
surfact
kaviratna
banerje
show
nanoprepar
improv
resist
pulmonari
surfact
inhibit
show
nanovesicl
aerosol
surfact
effect
acidinduc
lung
injuri
repres
novel
nanotechnologybas
noninvas
therapeut
strategi
ali
pulmonari
condit
leakag
inflammatori
inhibitor
agent
form
major
compon
pathophysiolog
recent
studi
zhu
et
al
develop
novel
dimethyl
silicon
dri
nanoemuls
inhal
dsni
pulmonari
deliveri
dsni
show
significantli
higher
antiali
effect
ali
rat
model
blank
dsni
dimethyl
silicon
aerosol
recent
ravikumar
et
al
develop
nanocarrierbas
gene
therapi
upregul
express
pulmonari
erythropoietin
receptor
anim
model
hyperox
lung
injuri
inhal
deliveri
result
mitig
acut
oxid
lung
damag
togeth
studi
suggest
aerosol
inhal
administr
nanocarrierbas
therapi
may
prove
effect
remedi
lung
injuri
optim
deliveri
drug
depend
given
patientspecif
lungairway
configur
suitabl
deliveri
devic
well
best
aerosol
characterist
inhal
condit
suitabl
deliveri
devic
help
gener
drug
aerosol
suffici
size
mass
deliv
distal
lung
region
along
inhal
aircarrierga
recent
year
sever
technic
advanc
led
inhal
effici
drug
deliveri
local
lung
region
novel
featur
dose
measur
breath
actuat
predetermin
drug
releas
significantli
improv
drug
deliveri
develop
drug
deliveri
methodolog
subsequ
devic
prototyp
requir
comput
fluidparticl
dynam
analysi
complex
transport
phenomena
well
experiment
ultim
clinic
test
deliv
nanomedicin
predetermin
site
human
lung
airway
challeng
offer
much
promis
combat
aliard
success
observ
studi
suggest
incid
advers
event
minim
aerosol
deliveri
howev
potenti
caus
system
local
toxic
form
airway
irrit
cough
often
bronchospasm
well
pulmonari
injuri
use
aerosol
therapi
research
includ
defin
safeti
profil
nanoparticl
deliv
via
aerosol
therapi
necessari
futur
anticip
nanomicel
also
applic
treat
inflammatori
lung
condit
copd
asthma
bronchiectasi
pulmonari
fibrosi
major
health
concern
militari
gener
popul
studi
need
establish
role
aerosol
nanoprepar
inhal
therapi
despit
advanc
understand
pathobiolog
ard
treatment
option
devast
condit
limit
nanomedicin
medic
applic
nanotechnolog
promis
endless
rang
applic
biomed
imag
drug
deliveri
therapeut
novel
approach
use
nanotechnolog
revolution
futur
medicin
nanoparticul
drug
deliveri
system
design
multifunct
engin
nanoparticl
appear
particularli
attract
promis
drug
deliveri
organ
lung
sinc
combin
sever
opportun
like
uniform
distribut
drug
dose
among
ventil
alveoli
allow
uniform
cellular
drug
intern
besid
sustain
releas
drug
plasma
organ
potenti
advantag
system
includ
possibl
reduct
drug
dosag
advers
effect
drug
interact
inhal
deliveri
nanoparticl
would
also
allow
target
deliveri
drug
minim
system
effect
although
field
nanomedicin
offer
multipl
opportun
still
infanc
research
proceed
order
obtain
specif
target
drug
combin
mode
deliveri
ongo
studi
offer
sever
excit
prospect
applic
engin
nanomedicin
prepar
aerosol
prepar
drug
deliveri
year
come
